Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBITDA (2020 - 2025)

Historic EBITDA for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$17.5 million.

  • Barinthus Biotherapeutics' EBITDA fell 174058.11% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.3 million, marking a year-over-year decrease of 8025.86%. This contributed to the annual value of -$63.7 million for FY2024, which is 68.88% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' EBITDA is -$17.5 million, which was down 174058.11% from -$12.8 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' EBITDA ranged from a high of $13.2 million in Q2 2022 and a low of -$30.9 million during Q4 2024
  • Over the past 5 years, Barinthus Biotherapeutics' median EBITDA value was -$15.0 million (recorded in 2025), while the average stood at -$11.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 23070.81% in 2022, then crashed by 218608.56% in 2023.
  • Over the past 5 years, Barinthus Biotherapeutics' EBITDA (Quarter) stood at -$16.7 million in 2021, then crashed by 50.55% to -$25.1 million in 2022, then skyrocketed by 62.13% to -$9.5 million in 2023, then crashed by 225.35% to -$30.9 million in 2024, then skyrocketed by 43.38% to -$17.5 million in 2025.
  • Its last three reported values are -$17.5 million in Q3 2025, -$12.8 million for Q2 2025, and -$15.0 million during Q1 2025.